SillaJen and Lee's Pharmaceutical Announce First Patient Enrolled in the PHOCUS Trial in China Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer
SillaJen Announces First Patient Enrolled in Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron’s Cemiplimab
SillaJen Poster Presentation at 2018 GU ASCO Symposium Highlights New Clinical Data in RCC, Intravenous Delivery of Pexa-Vec, Oncolytic Immunotherapy
Pexa-Vec is the most advanced product candidate. Pexa-Vec is engineered to selectively infect and replicate in cancer cells by exploiting the genetic changes that frequently occur in cancer cells.
JX-970 is next generation pipeline. In preclinical studies, JX-970 exerted tumor debulking effect and the same time demonstrated selective preference for tumor tissues.
Pexa-Vec (JX-594)
SillaJen is actively seeking development partners and/or licensing opportunities for all of its assets.
